Assembly Biosciences (FRA:V7B) Accounts Payable & Accrued Expense : €2.86 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Accounts Payable & Accrued Expense?

Assembly Biosciences's quarterly accounts payable & accrued expense declined from Sep. 2023 (€2.37 Mil) to Dec. 2023 (€1.47 Mil) but then increased from Dec. 2023 (€1.47 Mil) to Mar. 2024 (€2.86 Mil).

Assembly Biosciences's annual accounts payable & accrued expense increased from Dec. 2021 (€5.75 Mil) to Dec. 2022 (€6.33 Mil) but then declined from Dec. 2022 (€6.33 Mil) to Dec. 2023 (€1.47 Mil).

Assembly Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Assembly Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Accounts Payable & Accrued Expense Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

8.58

11.52

5.75

6.33

1.47

Assembly Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															4.60	2.97	2.37	1.47	2.86

Assembly Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Assembly Biosciences (FRA:V7B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ASMB:USA

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines